Prudential Financial
ACRS icon

Prudential Financial’s Aclaris Therapeutics ACRS Stock Holding History

Prudential Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.2K Buy
+13,380
New +$45.1K ﹤0.01% 2315
2019
Q2 		– Sell
-27,410
Closed -$164K – 2453
2019
Q1 		$164K Buy
27,410
+557
+2% +$3.69K ﹤0.01% 2338
2018
Q4 		$198K Buy
+26,853
New +$277K ﹤0.01% 2250

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prudential Financial's ACRS Position: Q1 2026 in Review

Prudential Financial opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 13,380 shares worth $50.2K. The stake represents ﹤0.01% of the portfolio and ranks #2315 among its holdings. This is a return to the name: Prudential Financial previously reported a position in ACRS as recently as Q1 2019.

Prudential Financial first reported a position in ACRS in Q4 2018 and has held it in 3 quarters since. The position peaked at $198K in Q4 2018. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Prudential Financial held 13,380 shares of Aclaris Therapeutics worth $50.2K as of Q1 2026.
  • Aclaris Therapeutics was a new Prudential Financial position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2315 holding.
  • Prudential Financial first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 3 quarters since.
  • Prudential Financial's Aclaris Therapeutics position peaked at $198K in Q4 2018.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.